Advertisement
Organisation › Details
Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *
Start | 2019-04-01 restructured | |
Group | Evotec (Group) | |
Predecessor | Evotec AG (FSE: EVT, TecDAX) | |
Industry | drug discovery technology | |
Industry 2 | drug discovery services | |
Person | Wojczewski, Christian (Evotec 202407– CEO before Mediq + Linde + McKinsey) | |
Region | Hamburg | |
Country | Germany | |
Street | 7 Essener Bogen | |
City | 22419 Hamburg | |
Address record changed: 2022-09-17 | ||
Basic data | Employees | G: 5,001 to 10,000 (2023-12-31) |
Currency | EUR | |
Annual sales | 781,426,000 (revenues, consolidated (2023) 2023-12-31) | |
Profit | -83,913,000 (2023-12-31) | |
Cash | 510,909,000 (2023-12-31) | |
* Document for »About Section«: Evotec AG. (5/31/18). "Press Release: Evotec Forms Academic Bridge »LAB591« with Arix Bioscience and Fred Hutchinson Cancer Research Center". Hamburg. | ||
Record changed: 2024-05-03 |
Advertisement
More documents for Evotec (Group)
- [1] Evotec SE. (4/23/24). "Press Release: Evotec SE Appoints Dr Christian Wojczewski as Chief Executive Officer". Hamburg....
- [2] Evotec SE. (4/17/24). "Press Release: Evotec Welcomes Aurélie Dalbiez as Chief People Officer". Hamburg....
- [3] Evotec SE. (3/6/24). "Press Release: Evotec and Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into the Clinic". Hamburg & Turin....
- [4] Evotec SE. (1/3/24). "Press Release: Evotec Announces CEO Transition. Dr. Werner Lanthaler to Step Down as CEO". Hamburg....
- [5] Evotec SE. (5/12/23). "Press Release: Evotec Publishes Annual Report 2022 and Quarterly Statement for Q1 2023". Hamburg....
- [6] Evotec SE. (5/30/22). "Press Release: Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand". Hamburg....
- [7] Evotec SE. (10/27/21). "Press Release: Evotec Announces First Funded Projects of Translational BRIDGE beLAB1407 in Collaboration with Bristol Myers Squibb". Hamburg....
- [8] Evotec SE. (7/5/21). "Press Release: Evotec Creates Long-term Growth Opportunities by Initiating »Campus Levi-Montalcini« in Verona"....
- [9] Evotec SE. (4/21/21). "Press Release: Evotec Invests into Oxford Cell Therapy Company OxVax"....
- [10] Exscientia Ltd.. (1/5/21). "Press Release: Exscientia Appoints Richard Law to Expand Its AI-drug discovery Partnering Business"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top